Doxorubicin With Cyclophosphamide Followed by Docetaxel Every 21 Days Compared With Doxorubicin and Docetaxel Every 14 Days As Preoperative Treatment in Operable Breast Cancer: The GEPARDUO Study of the German Breast Group
Top Cited Papers
- 20 April 2005
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (12) , 2676-2685
- https://doi.org/10.1200/jco.2005.05.078
Abstract
Dose-dense and sequential administration of cytotoxic drugs are current approaches to improve outcomes in patients with early-stage breast cancer. This phase III study investigated 913 women with untreated operable breast cancer (T2-3, N0-2, M0) randomly assigned to receive either doxorubicin 50 mg/m2 plus docetaxel 75 mg/m2 every 14 days for four cycles with filgrastim support (ADOC), or doxorubicin 60 mg/m2 plus cyclophosphamide 600 mg/m2 every 21 days followed by docetaxel 100 mg/m2 every 21 days for four cycles each (AC-DOC). The primary end point was the incidence of pathologic complete (invasive and noninvasive) response (pCR) in the breast and axillary nodes. Secondary end points were predictors for pCR, clinical response, rate of breast conservation, and safety. A pCR was achieved in 94 patients (10.6%), but the likelihood was significantly greater with AC-DOC (14.3%; n = 63) than with ADOC (7.0%; n = 31) (odds ratio, 2.22; 90% CI, 1.52 to 3.24; P < .001). Independent predictors of attaining a pCR included the use of sequential therapy, high tumor grade, and negative hormone receptor status. The response rates detected by palpation and by imaging were significantly higher with AC-DOC (85.0% and 78.6%, respectively) than with ADOC (75.2% and 68.6%, respectively; both P values < .001). The rate of breast-conserving surgery was 63.4% for AC-DOC and 58.1% for ADOC (P = .05). Predominant grade 3/4 toxicities were leucopenia (AC-DOC, 74.2%; ADOC, 53.7%) and neutropenia (AC-DOC, 66.4%; ADOC, 44.7%) but were infrequently associated with fever (AC-DOC, 4.6%; ADOC, 3.1%). Sequential AC-DOC is more effective at inducing pCR than dose-dense ADOC as preoperative treatment for patients with operable breast cancer.Keywords
This publication has 14 references indexed in Scilit:
- Meeting Highlights: Updated International Expert Consensus on the Primary Therapy of Early Breast CancerJournal of Clinical Oncology, 2003
- International Expert Panel on the Use of Primary (Preoperative) Systemic Treatment of Operable Breast Cancer: Review and RecommendationsJournal of Clinical Oncology, 2003
- Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancerBritish Journal of Cancer, 2002
- Neoadjuvant Chemotherapy in Breast Cancer: Significantly Enhanced Response With DocetaxelJournal of Clinical Oncology, 2002
- Preoperative Chemotherapy in Primary Operable Breast Cancer: Results From the European Organization for Research and Treatment of Cancer Trial 10902Journal of Clinical Oncology, 2001
- Maximized Reduction of Primary Breast Tumor Size Using Preoperative Chemotherapy With Doxorubicin and DocetaxelJournal of Clinical Oncology, 1999
- Clinical Course of Breast Cancer Patients With Complete Pathologic Primary Tumor and Axillary Lymph Node Response to Doxorubicin-Based Neoadjuvant ChemotherapyJournal of Clinical Oncology, 1999
- Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.Journal of Clinical Oncology, 1998
- Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18.Journal of Clinical Oncology, 1997
- Breast tumour response to primary chemotherapy predicts local and distant control as well as survivalEuropean Journal Of Cancer, 1995